PE78899A1 - Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona - Google Patents

Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona

Info

Publication number
PE78899A1
PE78899A1 PE1998000466A PE00046698A PE78899A1 PE 78899 A1 PE78899 A1 PE 78899A1 PE 1998000466 A PE1998000466 A PE 1998000466A PE 00046698 A PE00046698 A PE 00046698A PE 78899 A1 PE78899 A1 PE 78899A1
Authority
PE
Peru
Prior art keywords
piridil
etoxi
bencil
diona
thiazolidin
Prior art date
Application number
PE1998000466A
Other languages
English (en)
Spanish (es)
Inventor
Hamish Ross
Robin Price
Jeffrey Roger Granett
Jaikrishna Patel
Paul Nigel Wray
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of PE78899A1 publication Critical patent/PE78899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE1998000466A 1997-06-05 1998-06-05 Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona PE78899A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
PE78899A1 true PE78899A1 (es) 1999-10-22

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000466A PE78899A1 (es) 1997-06-05 1998-06-05 Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona

Country Status (29)

Country Link
EP (1) EP0998284A1 (no)
JP (1) JP2001521553A (no)
KR (1) KR20010013410A (no)
CN (3) CN1112926C (no)
AP (1) AP1214A (no)
AR (2) AR008198A1 (no)
AU (1) AU8215098A (no)
BG (1) BG104048A (no)
BR (1) BR9810405A (no)
CA (2) CA2292629C (no)
CO (1) CO4940400A1 (no)
DZ (1) DZ2510A1 (no)
EA (1) EA002384B1 (no)
GB (1) GB9711683D0 (no)
HU (1) HUP0004070A3 (no)
ID (1) ID24264A (no)
IL (1) IL133074A0 (no)
MX (1) MXPA99011322A (no)
NO (2) NO995938L (no)
NZ (2) NZ523725A (no)
OA (1) OA11306A (no)
PE (1) PE78899A1 (no)
PL (1) PL337201A1 (no)
SK (1) SK164899A3 (no)
TR (2) TR200002790T2 (no)
TW (1) TW570797B (no)
UY (1) UY25032A1 (no)
WO (1) WO1998055122A1 (no)
ZA (2) ZA9811572B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
UA67844C2 (uk) * 1999-04-23 2004-07-15 Смітклайн Бічам Плс Поліморф 5-[4-[2-(n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
DE60004658T2 (de) 1999-04-23 2004-06-24 Smithkline Beecham Plc, Brentford Thiazolidindionderivat und seine verwendung als antidiabetikum
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
DE06252444T8 (de) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
MX9603338A (es) * 1994-02-10 1997-03-29 Smithkline Beecham Plc Uso de sensibilizadores a la insulina para tratar enfermedades renales.
JPH11510508A (ja) * 1995-08-10 1999-09-14 ワーナー−ランバート・コンパニー インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
EP0921798A1 (en) * 1996-07-12 1999-06-16 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
AP9901696A0 (en) 1999-12-31
EP0998284A1 (en) 2000-05-10
AU8215098A (en) 1998-12-21
BR9810405A (pt) 2000-08-29
SK164899A3 (en) 2000-11-07
KR20010013410A (ko) 2001-02-26
NZ513922A (en) 2001-09-28
CN1112926C (zh) 2003-07-02
CA2292629C (en) 2004-01-06
TR199902963T2 (xx) 2000-02-21
TW570797B (en) 2004-01-11
CN1259050A (zh) 2000-07-05
TR200002790T2 (tr) 2001-11-21
CA2292629A1 (en) 1998-12-10
DZ2510A1 (fr) 2003-01-25
WO1998055122A1 (en) 1998-12-10
CN1526391A (zh) 2004-09-08
BG104048A (bg) 2000-07-31
NO995938L (no) 2000-02-02
AR015120A1 (es) 2001-04-18
ZA984826B (en) 1999-08-03
EA199901116A1 (ru) 2000-06-26
AR008198A1 (es) 1999-12-29
IL133074A0 (en) 2001-03-19
CO4940400A1 (es) 2000-07-24
NO995938D0 (no) 1999-12-03
HUP0004070A3 (en) 2002-03-28
HUP0004070A2 (hu) 2002-02-28
ID24264A (id) 2000-07-13
NO20040738L (no) 2000-02-02
JP2001521553A (ja) 2001-11-06
GB9711683D0 (en) 1997-08-06
ZA9811572B (en) 1999-07-22
CN1430959A (zh) 2003-07-23
AP1214A (en) 2003-10-08
CA2333352A1 (en) 1998-12-10
OA11306A (en) 2003-10-22
PL337201A1 (en) 2000-08-14
NZ523725A (en) 2004-09-24
UY25032A1 (es) 1998-11-26
MXPA99011322A (es) 2004-12-02
EA002384B1 (ru) 2002-04-25

Similar Documents

Publication Publication Date Title
PE78899A1 (es) Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
PE20001036A1 (es) Tabletas bioadhesivas para hidratacion progresiva y metodos para su elaboracion y uso
TR200001880T2 (tr) İtrakonazolün bir oral preparasyonunun bileşiği ve yöntemi.
PE20000550A1 (es) Composicion de un derivado de bencimidazol util como anti-viral y anti-hiv
AR019636A1 (es) Dispositivo para el acoplamiento de dientes de excavadoras.
MA30598B1 (fr) Composition pharmaceutique contenant un acide tetrahydrofolique.
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
BRPI0609515A8 (pt) Composto, composição farmacêutica, e, uso de um composto
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
EP1106210A3 (en) Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
JO2239B1 (en) Method for preparing benzothophen derivatives
EA199901100A1 (ru) Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин
ATE212991T1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
PE20000329A1 (es) Derivados de indol y composiciones farmaceuticas que los contienen
ES2188766T3 (es) Composicion farmaceutica que contiene lamotrigina.
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
EA200702648A1 (ru) Фармацевтическая композиция, пригодная для введения один раз в день
ES2180573T3 (es) Uso de derivados de indol como antagonistas de 5ht1.
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
DE69928500D1 (de) Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetate

Legal Events

Date Code Title Description
FC Refusal